Subjects
Healthy Korean male subjects aged 19-45 years with a body mass index of 18-27 kg/m2 were enrolled. They were defined by their previous medical and surgical history, physical examination, vital signs, 12-lead electrocardiography (ECG), and clinical laboratory tests. Those that had been exposed to any investigational products within 90 days prior to the first dosing in the study and those known to be hypersensitive to evogliptin or glimepiride, were excluded. All subjects provided a signed informed consent form before any study related procedure was performed.